176 related articles for article (PubMed ID: 37160922)
21. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.
Camacho FI; Mollejo M; Mateo MS; Algara P; Navas C; Hernández JM; Santoja C; Solé F; Sánchez-Beato M; Piris MA
Am J Surg Pathol; 2001 Oct; 25(10):1268-76. PubMed ID: 11688461
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
[TBL] [Abstract][Full Text] [Related]
23. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
24. p37Ing1b regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphomagenesis.
Coles AH; Marfella CG; Imbalzano AN; Steinman HA; Garlick DS; Gerstein RM; Jones SN
Cancer Res; 2008 Nov; 68(21):8705-14. PubMed ID: 18974112
[TBL] [Abstract][Full Text] [Related]
25. Aberrant V(D)J recombination is not required for rapid development of H2ax/p53-deficient thymic lymphomas with clonal translocations.
Bassing CH; Ranganath S; Murphy M; Savic V; Gleason M; Alt FW
Blood; 2008 Feb; 111(4):2163-9. PubMed ID: 17855626
[TBL] [Abstract][Full Text] [Related]
26. Suppression of thymic lymphomas and increased nonthymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene.
Tatemichi M; Tazawa H; Masuda M; Saleem M; Wada S; Donehower LA; Ohgaki H; Ohshima H
Int J Cancer; 2004 Oct; 111(6):819-28. PubMed ID: 15300793
[TBL] [Abstract][Full Text] [Related]
27. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities.
Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P
South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700
[TBL] [Abstract][Full Text] [Related]
28. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
29. The evolution of thymic lymphomas in p53 knockout mice.
Dudgeon C; Chan C; Kang W; Sun Y; Emerson R; Robins H; Levine AJ
Genes Dev; 2014 Dec; 28(23):2613-20. PubMed ID: 25452272
[TBL] [Abstract][Full Text] [Related]
30. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
[TBL] [Abstract][Full Text] [Related]
31. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Drexler HG
Leukemia; 1998 Jun; 12(6):845-59. PubMed ID: 9639410
[TBL] [Abstract][Full Text] [Related]
32. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
33. T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis.
Kuper-Hommel MJ; Schreuder MI; Gemmink AH; van Krieken JH
Mod Pathol; 2013 Mar; 26(3):421-7. PubMed ID: 23018871
[TBL] [Abstract][Full Text] [Related]
34. [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].
Li BZ; Zhou XY; Ye HT; Yang WT; Fan YZ; Lu HF; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2007 Dec; 36(12):819-24. PubMed ID: 18346354
[TBL] [Abstract][Full Text] [Related]
35. Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
Gailllard B; Cornillet-Lefebvre P; Le QH; Maloum K; Pannetier M; Lecoq-Lafon C; Grange B; Jondreville L; Michaux L; Nadal N; Ittel A; Luquet I; Struski S; Lefebvre C; Gaillard JB; Lafage-Pochitaloff M; Balducci E; Penther D; Barin C; Collonge-Rame MA; Jimenez-Poquet M; Richebourg S; Lemaire P; Defasque S; Radford-Weiss I; Bidet A; Susin SA; Nguyen-Khac F; Chapiro E;
Br J Haematol; 2021 Apr; 193(1):72-82. PubMed ID: 33314017
[TBL] [Abstract][Full Text] [Related]
36. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
Cai Q; Tu M; Xu-Monette ZY; Sun R; Manyam GC; Xu X; Tzankov A; Hsi ED; Møller MB; Medeiros LJ; Ok CY; Young KH
Mod Pathol; 2017 Jun; 30(6):854-876. PubMed ID: 28281555
[TBL] [Abstract][Full Text] [Related]
37. Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.
Schiefer AI; Kornauth C; Simonitsch-Klupp I; Skrabs C; Masel EK; Streubel B; Vanura K; Walter K; Migschitz B; Stoiber D; Sexl V; Raderer M; Chott A; da Silva MG; Cabecadas J; Müllauer L; Jäger U; Porpaczy E
Medicine (Baltimore); 2015 Dec; 94(52):e2388. PubMed ID: 26717387
[TBL] [Abstract][Full Text] [Related]
38. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
39. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment.
Singh AR; Peirce SK; Joshi S; Durden DL
Exp Cell Res; 2014 Sep; 327(1):78-90. PubMed ID: 24881819
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
